Risks of harm with cannabinoids, cannabis, and cannabis-based medicine for pain management relevant to patients receiving pain treatment: Protocol for an overview of systematic reviews

Ian Gilron, Fiona M. Blyth, Louisa Degenhardt, Marta Di Forti, Christopher Eccleston, Simon Haroutounian, Andrew Moore, Andrew S.C. Rice, Mark Wallace

Research output: Contribution to journalReview articlepeer-review

8 Citations (SciVal)

Abstract

Introduction:With the increasing availability of cannabis and cannabinoids and their potential utility for pain treatment, there is a growing need to evaluate the risk-benefit considerations of cannabinoids for the management of pain. As part of the IASP Cannabis and Cannabinoids Task Force, this protocol describes a planned overview of systematic reviews summarizing the risks of harm with cannabinoids that are relevant to patients receiving pain treatment.Methods:This overview will involve literature searches of several databases and a defined search strategy that will target systematic reviews or meta-analyses of cannabinoids where harms are the primary focus. Data extraction will include various features of the cannabinoid(s) and the harm(s) being studied as well as other methodological features of each included systematic review. Methodological quality of each included review will be assessed using AMSTAR-2 as well as compliance with the PRISMA harms checklist. Prospero registration pending.Discussion:The broad overview of reviews defined by this protocol is expected to synthesize available good quality evidence of harms that will help inform risk-benefit considerations about the use of cannabinoids for pain management.

Original languageEnglish
Article numbere742
Pages (from-to)1-3
Number of pages3
JournalPain Reports
Volume4
Issue number3
DOIs
Publication statusPublished - 1 May 2019

Funding

a Department of Anesthesiology and Perioperative Medicine, Kingston General Hospital, Queen’s University, Kingston, ON, Canada, b Centre for Neuroscience Studies, Queen’s University, Kingston, ON, Canada, c School of Policy Studies, Queen’s University, Kingston, ON, Canada, d University of Sydney Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, New South Wales, Australia, e National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia, f Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom, g National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London, Maudsley NHS Foundation Trust, King’s College London, London, United Kingdom, h South London and Maudsley NHS Mental Health Foundation Trust, London, United Kingdom, i Centre for Pain Research, The University of Bath, Bath, United Kingdom, j Division of Clinical and Translational Research, Department of Anesthesiology, Washington University Pain Center, Washington University School of Medicine, St Louis, MO, USA, k Nuffield Department of Clinical Neurosciences, University of Oxford, Pain Research, The Churchill, Oxford, United Kingdom, l Pain Research Group, Department Surgery and Cancer, Faculty of Medicine, Imperial College London, London, United Kingdom, m Department of Anesthesiology, University of California San Diego, San Diego, CA, USA I. Gilron is a co-principal investigator of the CIHR SPOR Canadian Pain Network (CPN). I. Gilron has received industry support from Adynxx, Biogen, Eupraxia, Novaremed, and Teva. I. Gilron is cochair of the Clinical Research Network of the CPN, which receives research support from Canopy Health, Toronto Poly Clinic, and CannTrust. L. Degenhardt has received untied educational grants from Reckitt Benckiser, Indivior, Munipharma, and Seqirus for the conduct of postmarketing surveillance studies of opioid medications. M. Di Forti reports grants from MRC and personal fees from Janssen, outside the submitted work. S. Haroutounian has received research support from Pfizer Inc (ASPIRE neuropathic pain grant program) and industry support from Medoc Ltd. A. Moore reports personal fees from Novartis and personal fees from RB, outside the submitted work. A.S.C. Rice reports other from International Association for Study of Pain, during the conduct of the study; personal fees from Imperial College Consultants; and other from Spinifex/Novartis, outside the This work was supported, in part, by the Queen’s University Department of Anesthesiology & Perioperative Medicine, and the Chronic Pain Network of the Canadian Institutes of Health Research Strategy on Patient-Oriented Research.

Keywords

  • Adverse effects
  • Adverse events
  • Cannabinoids
  • Cannabis
  • Clinical trials
  • Harms
  • Pain management

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Fingerprint

Dive into the research topics of 'Risks of harm with cannabinoids, cannabis, and cannabis-based medicine for pain management relevant to patients receiving pain treatment: Protocol for an overview of systematic reviews'. Together they form a unique fingerprint.

Cite this